**INTRODUCTION**

Angiosarcomas are extremely rare high-grade malignant tumors, accounting for less than 2% of soft tissue sarcomas (1). Approximately one third of angiosarcomas occur in skin, one third in soft tissue, and remaining one third in other sites including breast, liver, and bone. Cutaneous angiosarcoma occurs most commonly on the face and scalp in elderly patients and is also seen in association with chronic lymphedema (2).

It is estimated that less than 1% of all spontaneous pneumothorax are tumor-associated (3). Development of a spontaneous pneumothorax in patients with metastatic soft tissue sarcomas has been described in advanced diseases or during cytotoxic chemotherapy. However, the spontaneous bilateral pneumothorax is a rare complication of cancer chemotherapy.

Here we report a case of bilateral spontaneous pneumothorax after systemic chemotherapy in a male patient with a localized angiosarcoma of the scalp.

**CASE REPORT**

A 68-yr-old man is presented with an erythematous patchy induration on his scalp. There were no history of smoking, radiation, and trauma. There were no evidence of underlying lung lesion or any metastasis on his chest radiography. Therefore, systemic doxorubicin and dacarbazine were given. After nineteen days of chemotherapy, he developed a bilateral spontaneous pneumothorax and palpable cervical lymph nodes. Both parietal and visceral pleura were intact and showed no evidence of metastatic and pathologic lesions on thoracoscopic evaluation. The patient managed with bilateral tube thoracostomy and both lungs were expanded. Lymph nodes became unpalpable during three cycles of the paclitaxel and doxorubicin, however, bilateral lung metastases were developed and progressed despite chemotherapy. The patient died due to respiratory failure after five months. This report underlines that spontaneous pneumothorax can occur as the first manifestation of metastatic angiosarcoma even if imaging studies do not show of a metastatic lesion.

**Key Words**: Pneumothorax; Hemangiosarcoma; Scalp

---

**Bilateral Spontaneous Pneumothorax During Cytotoxic Chemotherapy for Angiosarcoma of the Scalp**: A Case Report

Spontaneous pneumothorax is a rare manifestation of metastatic lung cancers and described in advanced diseases or during cytotoxic chemotherapy which is manifested by sudden onset of dyspnea. The cause or mechanism of spontaneous pneumothorax has been unknown, as well as the association with site of metastases or type of cancers or side effect of chemotherapeutic drugs has been reported rarely. A 68-yr-old man underwent excision of angiosarcoma of the scalp. Chest radiography did not show any evidence of possible metastatic lung lesion at that time. Therefore, systemic doxorubicin and dacarbazine were given. After nineteen days of chemotherapy, he developed a bilateral spontaneous pneumothorax and palpable cervical lymph nodes. Both parietal and visceral pleura were intact and showed no evidence of metastatic and pathologic lesions on thoracoscopic evaluation. The patient managed with bilateral tube thoracostomy and both lungs were expanded. Lymph nodes became unpalpable during three cycles of the paclitaxel and doxorubicin, however, bilateral lung metastases were developed and progressed despite chemotherapy. The patient died due to respiratory failure after five months. This report underlines that spontaneous pneumothorax can occur as the first manifestation of metastatic angiosarcoma even if imaging studies do not show of a metastatic lesion.

**Key Words**: Pneumothorax; Hemangiosarcoma; Scalp

---

**Address for correspondence**
Keon Uk Park, M.D.
Department of Internal Medicine, Dongguk University Medical Center, 1090-1 Seokjang-dong, Gyeongju 780-350, Korea
Tel : +82.54-770-8210, Fax : +82.54-770-8500
E-mail : kupark@dumc.or.kr

---

**Received**: 26 February 2002
**Accepted**: 17 June 2002
dermis. Microscopy showed anastomotic channels lined by the endothelial cells and a cystic change with hemorrhage (Fig. 4). Tumor cells showed a positive immunohistochemical staining for factor 8, CD34, and CD31 (Fig. 5). Due to diffuse local spread of tumor, complete excision was impossible. The patient received combined systemic chemotherapy of doxorubicin (50 mg/m²) and dacarbazine (400 mg/m²). Nineteen days after the systemic chemotherapy, he was admitted to an emergency department with bilateral spontaneous pneumothorax (Fig. 1), and palpable cervical lymph
Pneumothorax After Chemotherapy of Angiosarcoma

nodes. Both parietal and visceral pleura were intact and showed no evidence of metastatic lesions on thoracoscopic evaluation. The patient was managed with bilateral closed thoracostomy and both lungs were expanded. Also he underwent pleurodesis with bleomycin and received three cycles of combined chemotherapy of paclitaxel (135 mg/m²) and doxorubicin (50 mg/m²). Lymph nodes disappeared, however, bilateral lung metastases were developed and progressed despite of systemic chemotherapy. He died of respiratory failure after five months.

**DISCUSSION**

Angiosarcomas are extremely rare high-grade malignant tumors arising from the vascular endothelium (4). Approximately half of the cases involve head and neck regions. The disease occurs most frequent in the sixth and seventh decades of life, with a male predilection (5).

Angiosarcomas are highly invasive tumors with the capacity to spread locally as well as distantly and have a rapid clinical course. Most angiosarcomas are metastasized at the time of diagnosis and have a poor prognosis of 2-24 months of survival from the time of detection due to frequent recurrence and early hematogenous metastases. The most common distant metastatic sites include the lung, liver, lymph nodes, and the skin (5, 6).

Kitagawa et al. (7) subdivided 95 autopsies of patients with angiosarcomas into a scalp group and a non-scalp group. The patients of the scalp group had more frequent pulmonary complications including pneumothorax, pulmonary hemorrhage, atelectasis, and pneumonia. In particular, pneumothorax was observed only in the scalp group, and was implicated in the extremely poor survival. Therefore, angiosarcomas of the scalp tend to metastasize to the lung, especially to the subpleural or pleural space, where these metastatic tumors are prone to necrosis, causing characteristic pulmonary complications.

Several theories regarding possible mechanisms of the bilateral pneumothorax in angiosarcomas have been put forward. First, the rupture of a subpleural bleb in a patient with an underlying chronic pulmonary disease is possible. Second, tumor nodules may act as ball valves to produce a partial bronchiolar obstruction and hyperinflation of alveoli. The rupture of an emphysematous bulla in an overexpanded portion of the lung produces a pneumothorax (8). Therefore, the disruption of peripheral visceral pleura or peripheral bronchioles causes a bronchopleural fistula (9). In our patient, thoracoscopic evaluation did not show any definite metastatic nodule or bulla. Third, the chemosensitivity of cancer may be considered. Tumors with an increased risk of developing a pneumothorax include Ewing’s sarcoma, Wilms’ tumor, teratoma, and synovial sarcoma (10). Osteosarcomas are thought to be the most common metastatic tumor causing a spontaneous pneumothorax (11). Fourth, the side effects of chemotherapeutic agents have been considered due to the temporal relationship between the use of combination chemotherapy and the development of pneumothorax. For example, Devereux et al. suggested that doxorubicin was the chemotherapeutic agent most likely to impair the wound healing with tissue repair, and may consequently predispose patients with pulmonary metastasis to pneumothorax (12). In this case, doxorubicin was included in the cytotoxic regimen, however, it is difficult to relate its direct effect on pneumothorax.

Until now, no established chemotherapy has been available for angiosarcomas, since systemic chemotherapy is ineffective in the disease with metastatic lesions. Therapy for angiosarcomas involves an early wide local excision, if possible. Early surgery and wide-field postoperative radiation therapy may offer the highest cure rate (1). Recently, however, paclitaxel showed a good response in 28 patients with scalp angiosarcomas with complete resolution of skin nodules and a partial response to metastatic lung lesions in phase II trials (13). Our patient was treated with paclitaxel (Taxol®) at a dose of 135 mg/m² for three cycles. Lymph nodes were not palpated after three cycles with systemic chemotherapy but lung metastases were developed lately.

Fenlon et al. stated that a pneumothorax resulting from a bronchopleural fistula complicating chemotherapy may prove to be resistant to conventional treatment (repeated closed-tube thoracostomy, suction drainage, and pleurodesis), and thus required a bilateral thoracostomy and pleurectomy (10). Metastases are sometimes confirmed by high-resolution computed tomography (CT) or transthoracic needle aspiration biopsy. Metastatectomy via thoracotomy or median sternotomy are sometimes employed (14). Early detection
of lung metastases is difficult, and Furrer et al. suggested that imaging studies such as chest radiography and CT are suboptimal for detecting micro-lesions and that sometimes pneumothorax could be the first and only evidence for metastases (9).

In this case, metastatic lesions could not be noted in the initial chest radiography and CT. However, with the delayed detection of diffuse bilateral lung metastases, we are able to presume that micrometastases were already occurred even before it could be detected by imaging studies.

This report underlines that pneumothorax can occurs as the first manifestation of metastatic angiosarcoma even if imaging studies are not indicative of metastatic disease.

REFERENCES

1. Fata F, O’Reilly E, Ilson D, Pfister D, Kelsen DP, Schwartz GK, Casper ES. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999; 86: 2034-7.
2. Schulman P, Cheng E, Cvitkovic E, Golbey R. Spontaneous pneumothorax as a result of intensive cytotoxic chemotherapy. Chest 1979; 75: 194-6.
3. Dines DE, Cortese DA, Brennan MD, Hahn RG, Payne WS. Malignant pulmonary neoplasms predisposing to spontaneous pneumothorax. Mayo Clin Proc 1973; 48: 541-4.
4. Orchard GE, Zelger B, Jones EW, Jones RR. An immunocytochemical assessment of 19 cases of cutaneous angiosarcoma. Histopathology 1996; 28: 235-40.
5. Mark RJ, Tran LM, Sercarz J, Fu YS, Calcaterra TC, Juliard GF. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg 1993; 119: 973-8.
6. Fakih MG, Defrances MC, Ohiro NP, Ramanathan RK. Unusual tumors involving the head and neck region: Case 1. Angiosarcoma of the scalp. J Clin Oncol 2001; 19: 4173-4.
7. Kitagawa M, Tanaka I, Takemura T, Matsubara O, Kasuga T. Angiosarcoma of the scalp: report of two cases with fatal pulmonary complications and a review of Japanese autopsy registry data. Virchows Arch A Pathol Anat Histopathol 1987; 412: 83-7.
8. Lawton PA, Knowles S, Karp SI, Suvana SK, Spittle MF. Bilateral pneumothorax as a presenting feature of metastatic angiosarcoma of the scalp. Br J Radiol 1990; 63: 132-4.
9. Furrer M, Althaus U, Ris HB. Spontaneous pneumothorax from radiographically occult metastatic sarcoma. Eur J Cardiothorac Surg 1997; 11: 1171-3.
10. Fenlon HM, Carney D, Breathnach E. Case report. bilateral recurrent tension pneumothorax complicating combination chemotherapy for soft tissue sarcoma. Clin Radiol 1996; 51: 302-4.
11. D’Angio GJ, Iannocone G. Spontaneous pneumothorax as a complication of pulmonary metastases in malignant tumors in childhood. Am J Roentgenol 1961; 86: 1092-102.
12. Devereux DF, Thibault T, Boretos J, Brennan MF. The quantitative and qualitative impairment of wound healing by Adriamycin. Cancer 1979; 43: 932-8.
13. Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR. Phase II trial of paclitaxel in patients with soft tissue sarcoma. Cancer Invest 1998; 16: 442-6.
14. Jones DR, Tanguilig GG, Grauer GM. Thoracoscopic resection of bilateral metastatic sarcomas causing spontaneous pneumothorax. Chest 1994; 106: 1274-6.